IPSC CENTURY THERAPEUTICS INC

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY.

A live webcast of the presentation will be available on the Investors page of Century’s website at . An archived replay will be available for at least 30 days.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases and cancer. The company’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit and connect with us on LinkedIn.

For More Information:

Century Therapeutics

Douglas Carr

Senior Vice President, Finance

JPA Health

Sarah McCabe



EN
14/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTURY THERAPEUTICS INC

 PRESS RELEASE

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medici...

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY. A live webcast of the presentation will be available on ...

 PRESS RELEASE

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global ...

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. In addition, members of management will be available for me...

 PRESS RELEASE

Century Therapeutics Reports Second Quarter 2025 Financial Results and...

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functionally comparable to primary T cells, now in IND-enabling studies as a potential treatment for B-cell-mediated diseases; program expected to progress into the clinic in 2026 Dr. Brent Pfeiffenberger, CEO, appointed to Board ChairCash runway extended into fourth quarter 2027 PHILADELPHIA, Aug. 14, 2025 ...

 PRESS RELEASE

Century Therapeutics Announces Two Upcoming Presentations at the EULAR...

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting the compan...

 PRESS RELEASE

Century Therapeutics Reports First Quarter 2025 Financial Results and ...

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived ’tunable’ CD4+/CD8+ ab T cells and ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch